Archive · 11 Nov 2025
Granules Life Sciences Facility Receives First USFDA Approval
A part of a company called Granules India, named Granules Life Sciences, just got some important news from the United States.
The US Food and Drug Administration, which is like the health police for food and medicine in America, has given their factory in Hyderabad, India, the green light.
This means the factory can now make a specific medicine for the US market.
They had a check-up for this medicine a few months ago, and even though the inspectors found one small thing to mention, the company fixed it.
Now, this factory is officially approved and can help make more medicines, which is good for the company's business and makes sure they can keep making medicines even if one factory has a problem.
Granules Life Sciences (GLS) in Hyderabad has received its first USFDA approval.
The approval is for a product that underwent a pre-approval inspection by the USFDA between July 28 and August 1, 2025.
One observation was made during the inspection, and GLS submitted a timely response.
This approval marks a significant milestone for Granules India's finished dosage manufacturing capabilities.
GLS plans to launch the approved product in the US, aiming to strengthen market share and ensure business continuity.
- Who
- Granules Life Sciences (GLS), an arm of Granules India
- What
- Received its first approval from the USFDA for its Hyderabad facility for a product.
- When
- Approval announced November 11, 2025, following an inspection from July 28 to August 1, 2025.
- Where
- Hyderabad, India
- Why
- The approval allows GLS to expand its finished dosage manufacturing capabilities and strengthen market share in the US.
- Company
- Granules Life Sciences (GLS), an arm of Granules India
- Approval Body
- US Food and Drug Administration (USFDA)
- Facility Location
- Hyderabad
- Inspection Dates
- July 28 - August 1, 2025
- Product Status
- First product approval received
- Date of Release
- November 11, 2025